RUVITE Drug Patent Profile
✉ Email this page to a colleague
When do Ruvite patents expire, and what generic alternatives are available?
Ruvite is a drug marketed by Savage Labs and is included in one NDA.
The generic ingredient in RUVITE is cyanocobalamin. There are nine drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the cyanocobalamin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ruvite
A generic version of RUVITE was approved as cyanocobalamin by PADAGIS ISRAEL on September 9th, 2020.
Summary for RUVITE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 92 |
Formulation / Manufacturing: | see details |
DailyMed Link: | RUVITE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for RUVITE
US Patents and Regulatory Information for RUVITE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Savage Labs | RUVITE | cyanocobalamin | INJECTABLE;INJECTION | 080570-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |